Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

Area of Science:

• Oncology
• Immunology
• Hepatology

Background:

• Hepatocellular carcinoma (HCC) is a prevalent and increasing global cancer.
• Understanding the tumor immune microenvironment is crucial for HCC treatment.
• Immunotherapy has emerged as a significant therapeutic option for HCC.

Purpose of the Study:

• To review the recent research progress of immune checkpoint inhibitors (ICIs) in HCC treatment.
• To discuss the existing challenges and limitations of ICIs in managing HCC.
• To highlight the role of ICIs in modulating the tumor immune microenvironment.

Main Methods:

• Review of current literature on ICIs for HCC.
• Analysis of clinical trial data and research findings.
• Discussion of immune mechanisms targeted by ICIs.

Main Results:

• Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 are widely used in HCC.
• ICIs effectively reactivate anti-tumor immune responses by disrupting T cell co-inhibitory signals.
• Significant advancements have been made in ICI therapy for HCC patients.

Conclusions:

• ICIs represent a promising therapeutic strategy for HCC.
• Further research is needed to overcome existing problems and optimize ICI efficacy.
• Modulating the tumor immune microenvironment is key to successful HCC immunotherapy.